MedTrace Logo

A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors

NCT02834247 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2023-02-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D), safety and efficacy of TAK-659 in combination with nivolumab in participants with advanced solid tumors.

Conditions

  • Triple-Negative Breast Neoplasms
  • Carcinoma, Non-Small-Cell Lung
  • Head and Neck Carcinoma, Squamous Cell
  • Advanced Solid Tumors

Interventions

DRUG

TAK-659

TAK-659 Tablets.

DRUG

Nivolumab

Nivolumab intravenous infusion.

Sponsors & Collaborators

  • Calithera Biosciences, Inc

    lead INDUSTRY

Principal Investigators

  • Medical Director Clinical Science · Millennium Pharmaceuticals, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-12
Primary Completion
2018-11-30
Completion
2018-11-30
FDA Drug
Yes

Countries

  • United States
  • Italy
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02834247 on ClinicalTrials.gov